Acute Stroke Treatment in an Anticoagulated Patient: When Is Thrombolysis an Option?

[1]  Ana Catarina Fonseca,et al.  European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke , 2021, European stroke journal.

[2]  T. Meinel,et al.  Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  E. Carrera,et al.  Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation , 2020, Annals of neurology.

[4]  J. Purrucker,et al.  Etiology of Ischemic Strokes of Patients with Atrial Fibrillation and Therapy with Anticoagulants , 2020, Journal of clinical medicine.

[5]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[6]  S. Schwab,et al.  Letter by Kallmünzer et al Regarding Article, "Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: a Systematic Review and Meta-Analysis". , 2020, Stroke.

[7]  Sandy Park,et al.  Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation , 2020, Circulation. Cardiovascular quality and outcomes.

[8]  J. Leeds,et al.  A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. , 2020, Blood advances.

[9]  A. Ranta,et al.  Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort , 2020, Neurology.

[10]  D. Werring,et al.  Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation , 2020, Annals of neurology.

[11]  T. Neumann-Haefelin,et al.  Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases , 2020, International journal of stroke : official journal of the International Stroke Society.

[12]  T. Iwama,et al.  Guidelines for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: A Guideline from the Japan Stroke Society , 2019, Neurologia medico-chirurgica.

[13]  Correction to: Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. , 2019, Stroke.

[14]  W. Powers,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. , 2019, Stroke.

[15]  S. Schwab,et al.  Direct Oral Anticoagulant Plasma Levels for the Management of Acute Ischemic Stroke , 2019, Cerebrovascular Diseases.

[16]  T. Meinel,et al.  Stroke severity in patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists , 2019, Journal of Neurology.

[17]  M. Crowther,et al.  Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum , 2019, American journal of hematology.

[18]  T. Meinel,et al.  Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants – A systematic review , 2019, PloS one.

[19]  A. Demchuk,et al.  Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors , 2019, The New England journal of medicine.

[20]  D. Fitzmaurice,et al.  Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation: Results From the GARFIELD-AF Registry , 2019, Circulation.

[21]  C. Nolte,et al.  Cohort profile: Thrombolysis in Ischemic Stroke Patients (TRISP): a multicentre research collaboration , 2018, BMJ Open.

[22]  R. Mikulík,et al.  Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience. , 2018, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[23]  M. Koga,et al.  Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations , 2018, Journal of stroke.

[24]  A. Camm,et al.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[25]  S. Ricci,et al.  Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab: case series and systematic review , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[26]  G. Donnan,et al.  Prehospital idarucizumab prior to intravenous thrombolysis in a mobile stroke unit , 2018, International journal of stroke : official journal of the International Stroke Society.

[27]  S. Susen,et al.  Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants , 2018, European journal of neurology.

[28]  A. Luft,et al.  Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage , 2018, Annals of neurology.

[29]  G. Tsivgoulis,et al.  Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants , 2018, Stroke.

[30]  M. Mishina,et al.  The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non‐valvular atrial fibrillation , 2017, European journal of neurology.

[31]  S. Marsch,et al.  Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice , 2017, Journal of stroke.

[32]  S. Golaszewski,et al.  Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence , 2017, CNS Drugs.

[33]  C. Stellbrink,et al.  Kommentar zu den 2016 Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management von Vorhofflimmern , 2017, Der Kardiologe.

[34]  Michael J Pencina,et al.  Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation , 2017, JAMA.

[35]  U. Ziemann,et al.  Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants , 2017, Critical Care.

[36]  P. Bovi,et al.  Continuation of direct oral anticoagulants in the acute phase of ischemic stroke. A case series , 2017, Journal of Thrombosis and Thrombolysis.

[37]  Eric E. Smith,et al.  Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before Stroke , 2017, Circulation.

[38]  H. Diener,et al.  Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion , 2017, International journal of stroke : official journal of the International Stroke Society.

[39]  E. V. Van Cott,et al.  An Assessment of the State of Current Practice in Coagulation Laboratories. , 2016, American journal of clinical pathology.

[40]  T. Steiner,et al.  Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used? , 2016, International journal of stroke : official journal of the International Stroke Society.

[41]  D. Fitzmaurice,et al.  Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF , 2016, European heart journal.

[42]  U. Ziemann,et al.  Point-of-Care Testing of Coagulation in Patients Treated With Non–Vitamin K Antagonist Oral Anticoagulants , 2015, Stroke.

[43]  Bcps,et al.  Idarucizumab for dabigatran reversal , 2015 .

[44]  B. Kim,et al.  Ischemic Stroke on Optimal Anticoagulation with Novel-Oral Anticoagulants Compared with Warfarin , 2015, International journal of stroke : official journal of the International Stroke Society.

[45]  Eric E. Smith,et al.  Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Guidelines, Update 2014 , 2015, International journal of stroke : official journal of the International Stroke Society.

[46]  E. Herrmann,et al.  Point-of-Care Coagulation Testing for Assessment of the Pharmacodynamic Anticoagulant Effect of Direct Oral Anticoagulant , 2014, Therapeutic drug monitoring.

[47]  S. Messé,et al.  Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology , 2014, Neurology.

[48]  L. Wilkins.  Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology , 2014, Neurology.

[49]  Erika G Cordova,et al.  Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. , 2014, The Cochrane database of systematic reviews.

[50]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[51]  A. Deal,et al.  Performance of coagulation tests in patients on therapeutic doses of rivaroxaban , 2014, Thrombosis and Haemostasis.

[52]  S. Engelter,et al.  Intravenous thrombolysis in stroke patients receiving rivaroxaban , 2014, European journal of neurology.

[53]  K. Lees,et al.  Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin , 2013, Annals of neurology.

[54]  A. Winkler,et al.  Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross‐sectional pharmacodynamic study based on peak and trough plasma levels , 2013, Journal of thrombosis and haemostasis : JTH.

[55]  A. Camm,et al.  EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. , 2013, European heart journal.

[56]  R. Kim,et al.  Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. , 2013, The Canadian journal of cardiology.

[57]  E. Favaloro,et al.  Laboratory testing for the new oral anticoagulants: a review of current practice. , 2013, Pathology.

[58]  H. Diener,et al.  Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban , 2013, Clinical Research in Cardiology.

[59]  H. Nar,et al.  A specific antidote for dabigatran: functional and structural characterization. , 2013, Blood.

[60]  A. Alexandrov,et al.  Thrombolysis in Stroke Despite Contraindications or Warnings? , 2013, Stroke.

[61]  W. Hacke,et al.  Oral Anticoagulants – A Frequent Challenge for the Emergency Management of Acute Ischemic Stroke , 2012, Cerebrovascular Diseases.

[62]  Eric E. Smith,et al.  Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. , 2012, JAMA.

[63]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[64]  A. Clemens,et al.  Interpretation of point-of-care INR results in patients treated with dabigatran. , 2012, The American journal of medicine.

[65]  Jason C. Fish,et al.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[66]  L. Baruch,et al.  Potential Inaccuracy of Point-of-Care INR in Dabigatran-Treated Patients , 2011, The Annals of pharmacotherapy.

[67]  M. Feuring,et al.  Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.

[68]  W. Hacke,et al.  Point-of-Care International Normalized Ratio Testing Accelerates Thrombolysis in Patients With Acute Ischemic Stroke Using Oral Anticoagulants , 2009, Stroke.

[69]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[70]  P. Koudstaal,et al.  Anticoagulants Versus Antiplatelet Therapy for Preventing Stroke in Patients With Nonrheumatic Atrial Fibrillation and a History of Stroke or Transient Ischemic Attack , 2005, The Cochrane database of systematic reviews.

[71]  P. Koudstaal,et al.  Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. , 2004, The Cochrane database of systematic reviews.

[72]  P. Heuschmann,et al.  Coagulation Testing in Acute Ischemic Stroke Patients Taking Non–Vitamin K Antagonist Oral Anticoagulants , 2017, Stroke.

[73]  D. Siegal,et al.  Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review , 2017, Chest.

[74]  G. D. De Marchis,et al.  Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke , 2016, Journal of Thrombosis and Thrombolysis.

[75]  Gordon H. Guyatt,et al.  Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis , 2011 .

[76]  P Trouillas,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. , 1998, Lancet.